Soluble CD95 Ligand Role in the Pathophysiology of Non-infectious Active Uveitis

Non-Infectious Active Uveitis Clinical Trial

— UVE-FAS  

Official title:

Soluble CD95 Ligand Role in the Pathophysiology of Non-infectious Active Uveitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04354909
• Other study ID #: CHUBX 2019/43
• Status: Completed
• Start date: November 17, 2020
• Est. completion date: March 10, 2023

Study information

• Verified date: May 2024
• Source: University Hospital, Bordeaux
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study aims at defining the role of soluble CD95 Ligand in the physiopathology of the non-infectious uveitis. Soluble CD95 Ligand might have a prognostic interest as well as potential for the discovery of new therapeutic strategies

Description:

Non-Infectious active uveitis is a severe inflammatory ocular disease which can expose to the blindness. Actually, the knowledge of the physiopathology of uveitis stay poorly. CD95 Ligand (CD95-L) belongs to a TNF (tumor necrosis factors) receptor family. It knows to play a preponderant role to maintain the eye immune privilege. In particular conditions depending on immunologic environment, CD95-L has pro-inflammatory properties and can interact with Th17 lymphocytes and neutrophils, two cells implicated in non-infectious uveitis. The hypothesis is that s-CD95-L levels might be a prognostic factor in non-infectious uveitis and the study of the molecular mechanisms involved could provide new therapeutic targets.

This study will recruit 100 patients with non-infectious uveitis followed in Bordeaux University Hospital. Among classical disease activity information, blood samples will be collected during to assess s-CD95-L. Fundamental research will be realized on patients' sample to evaluate underlying molecular mechanisms.

Clinical and biological disease activity, treatment and outcomes will be studied in correlation with s-CD95-L to describe their potential prognostic role. Patients will be followed at regular intervals, accordingly to usual care.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: March 10, 2023
• Est. primary completion date: March 10, 2023
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of non-infectious uveitis according to the SUN (Standardization of the Uveitis Nomenclature) working Group;

• Age = 18 years;

• being affiliated to health insurance,

• willing to participate.

Exclusion Criteria:

• Pregnant or breastfeeding women,

• patient under legal protection measure ,

• poor understanding of the French language

Related Conditions & MeSH terms

• Non-Infectious Active Uveitis
• Uveitis

Intervention

Other:
• s-CD95-L
levels of s-CD95-L (ELISA test)

Locations

Country	Name	City	State
France	CHU Bordeaux	Bordeaux

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	levels of s-CD95-L	levels of s-CD95-L (ELISA test) in sera of non-infectious uveitis patients	Baseline
Secondary	Correlation between levels of s-CD95-L and Disease activity score	Correlation between levels of s-CD95-L and Disease activity score (as defined by ophthalmologic examination)	Baseline, Month 3
Secondary	Th17 dosage	Th17 dosage	Baseline, Month 3
Secondary	polynuclear neutrophils levels	polynuclear neutrophils levels (Flow cytometry)	Baseline, Month 3